Crispr Therapeutics AG plans to launch an initial public offering to raise up to $90 million, according to a late Friday filing with the Securities and Exchange Commission. Basel, Switzerland-based Crispr develops therapies based on its eponymous gene-editing technology. For the six months of 2016, the company reported collaboration revenue of $1.3 million and a loss of $4.66 a share. Crispr listed Citigroup, Piper Jaffray, Barclays, and Guggenheim Securities as underwriters. The company plans to list on the Nasdaq Global markets exchange under the ticker symbol "CRSP".